Cargando…

MAX inactivation is an early event in GIST development that regulates p16 and cell proliferation

KIT, PDGFRA, NF1 and SDH mutations are alternate initiating events, fostering hyperplasia in gastrointestinal stromal tumours (GISTs), and additional genetic alterations are required for progression to malignancy. The most frequent secondary alteration, demonstrated in ∼70% of GISTs, is chromosome 1...

Descripción completa

Detalles Bibliográficos
Autores principales:	Schaefer, Inga-Marie, Wang, Yuexiang, Liang, Cher-wei, Bahri, Nacef, Quattrone, Anna, Doyle, Leona, Mariño-Enríquez, Adrian, Lauria, Alexandra, Zhu, Meijun, Debiec-Rychter, Maria, Grunewald, Susanne, Hechtman, Jaclyn F., Dufresne, Armelle, Antonescu, Cristina R., Beadling, Carol, Sicinska, Ewa T., van de Rijn, Matt, Demetri, George D., Ladanyi, Marc, Corless, Christopher L., Heinrich, Michael C., Raut, Chandrajit P., Bauer, Sebastian, Fletcher, Jonathan A.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group 2017
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5344969/ https://www.ncbi.nlm.nih.gov/pubmed/28270683 http://dx.doi.org/10.1038/ncomms14674

Ejemplares similares

Genomic aberrations in cell cycle genes predict progression of KIT-mutant gastrointestinal stromal tumors (GISTs)
por: Heinrich, Michael C., et al.
Publicado: (2019)

Altered chromosomal topology drives oncogenic programs in SDH-deficient GISTs
por: Flavahan, William A, et al.
Publicado: (2019)

Post-Transcriptional Dysregulation by miRNAs Is Implicated in the Pathogenesis of Gastrointestinal Stromal Tumor [GIST]
por: Kelly, Lorna, et al.
Publicado: (2013)

Dystrophin Is a Tumor Suppressor in Human Cancers with Myogenic Programs
por: Wang, Yuexiang, et al.
Publicado: (2014)

Quadruple wild-type (WT) GIST: defining the subset of GIST that lacks abnormalities of KIT, PDGFRA, SDH, or RAS signaling pathways
por: Pantaleo, Maria A, et al.
Publicado: (2015)

Integrated genomic study of quadruple-WT GIST (KIT/PDGFRA/SDH/RAS pathway wild-type GIST)
por: Nannini, Margherita, et al.
Publicado: (2014)

Effect of gastrointestinal resection on sunitinib exposure in patients with GIST
por: de Wit, Djoeke, et al.
Publicado: (2014)

Differential antitumor activity of compounds targeting the ubiquitin-proteasome machinery in gastrointestinal stromal tumor (GIST) cells
por: Rausch, Jessica L., et al.
Publicado: (2020)

KIT exon 10 variant (c.1621 A > C) single nucleotide polymorphism as predictor of GIST patient outcome
por: Brahmi, Mehdi, et al.
Publicado: (2015)

A GIST or not a GIST? That is the question
por: Chrysanthos, Nikolaos, et al.
Publicado: (2014)

SDHC methylation in gastrointestinal stromal tumors (GIST): a case report
por: Urbini, Milena, et al.
Publicado: (2015)

Complementary activity of tyrosine kinase inhibitors against secondary kit mutations in imatinib-resistant gastrointestinal stromal tumours
por: Serrano, César, et al.
Publicado: (2019)

Correction: Complementary activity of tyrosine kinase inhibitors against secondary kit mutations in imatinib-resistant gastrointestinal stromal tumours
por: Serrano, César, et al.
Publicado: (2019)

Synchronous double gastric tumors: GIST or not GIST
por: Sayida, Sa’d, et al.
Publicado: (2020)

Recombinant erythropoietin for the anaemia of patients with advanced Gastrointestinal Stromal Tumours (GIST) receiving imatinib: an active agent only in non progressive patients
por: Duffaud, Florence, et al.
Publicado: (2012)

NTRK insights: best practices for pathologists
por: Hechtman, Jaclyn F.
Publicado: (2021)

GIST and Ghrelin: To Be or Not to Be?
por: Spiridon, Irene Alexandra, et al.
Publicado: (2021)

Outcomes of patients with metastatic gastrointestinal stromal tumors (GIST) treated with multi-kinase inhibitors other than imatinib as first-line treatment
por: Boilève, Alice, et al.
Publicado: (2020)

Identifying patients with NTRK fusion cancer
por: Solomon, J P, et al.
Publicado: (2019)

Clinical implications of mutational analysis in gastrointestinal stromal tumours
por: Hoeben, A, et al.
Publicado: (2008)

A rare case of atypical/anaplastic meningioma with MDM2 amplification
por: Wylleman, Robbert, et al.
Publicado: (2018)

Reintroduction of Imatinib in GIST
por: Reid, T.
Publicado: (2013)

Fistulizing Gastric GIST
por: Costa, Mariana, et al.
Publicado: (2015)

ETV1 is a lineage-specific survival factor in GIST and cooperates with KIT in oncogenesis
por: Chi, Ping, et al.
Publicado: (2010)

Molecular profiling of pre- and post-treatment pediatric high-grade astrocytomas reveals acquired increased tumor mutation burden in a subset of recurrences
por: Wood, Matthew D., et al.
Publicado: (2023)

Gastrointestinal Stromal Tumours (GISTs) with KRAS Mutation: A Rare but Important Subset of GISTs
por: Mullen, Dorinda, et al.
Publicado: (2023)

Detection of MDM2 amplification by shallow whole genome sequencing of cell-free DNA of patients with dedifferentiated liposarcoma
por: Przybyl, Joanna, et al.
Publicado: (2022)

Targeted therapy and personalized medicine in gastrointestinal stromal tumors: drug resistance, mechanisms, and treatment strategies
por: Li, George Z, et al.
Publicado: (2019)

Gist of art : principles and practise expounded in the classroom and studio
por: Sloan, John, 1871-1951
Publicado: (1977)

Clinical and therapeutic considerations of GIST
por: Gheorghe, M, et al.
Publicado: (2014)

GASTRIC SCHWANNOMA: THE GIST SIMULATOR
por: FIGUEROA-GIRALT, Manuel, et al.
Publicado: (2021)

Long term survival results for gastric GIST: is laparoscopic surgery for large gastric GIST feasible?
por: Kim, Ki-Han, et al.
Publicado: (2012)

What’s in a Gist? Towards an Unsupervised Gist Representation for Few-Shot Large Document Classification
por: Mar, Jaron, et al.
Publicado: (2020)

Inhibitor of Apoptosis Proteins (IAPs) are commonly dysregulated in GIST and can be pharmacologically targeted to enhance the pro-apoptotic activity of imatinib
por: Falkenhorst, Johanna, et al.
Publicado: (2016)

YWHAE-NUTM2 oncoprotein regulates proliferation and cyclin D1 via RAF/MAPK and Hippo pathways
por: Ou, Wen-Bin, et al.
Publicado: (2021)

Management of Recurrent Retroperitoneal Sarcoma
por: Jolissaint, Joshua S., et al.
Publicado: (2023)

Retained Mismatch Repair Protein Expression Occurs in Approximately 6% of Microsatellite Instability-High Cancers and is Associated with Missense Mutations in Mismatch Repair Genes.
por: Hechtman, Jaclyn F., et al.
Publicado: (2019)

Cellular Angiofibroma of the Prostate: A Rare Tumor in an Unusual Location
por: Wyn, Inez, et al.
Publicado: (2014)

Gastrointestinal stromal tumors (GISTs) of the stomach: a multicenter, retrospective study of curatively resected gastric GISTs
por: Kim, In-Hwan, et al.
Publicado: (2014)

TIPE2 acts as a biomarker for GIST risk category and suppresses the viability and invasiveness of GIST cells
por: Li, Zequn, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_7pu52k62sb43viho1lct6ec2qr